4 completed. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow Sclerosis: new trials by email Literature Review of Sclerosis trials Research Report on Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) Simtuzumab, Placebo - Primary Sclerosing Cholangitis (PSC) | Phase 2 | Completed | Gilead Sciences | 235 | 2013-03-04 | 2019-10-22 |
| A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) LY2127399, Placebo - Relapsing-Remitting Multiple Sclerosis | Phase 2 | Completed | Eli Lilly and Company | 245 | 2009-04-01 | 2018-11-15 |
| Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease Levetiracetam - Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Duke University | 20 | 2006-05-01 | 2013-06-19 |
| Scleroderma: Cyclophosphamide or Transplantation mHSCT, cyclophosphamide - Scleroderma, Systemic, Sclerosis | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 75 | 2005-06-01 | 2023-04-12 |
Amyotrophic Lateral Sclerosis (1) · Autoimmune Diseases (1) · Cholangitis, Sclerosing (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Motor Neuron Disease (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Muscle Cramp (1) · Muscle Spasticity (1) · Muscular Atrophy, Spinal (1) · Recurrence (1) · Scleroderma, Systemic (1)
Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Immune System Diseases (2) · Nervous System Diseases (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Bile Duct Diseases (1) · Biliary Tract Diseases (1) · Central Nervous System Diseases (1) · Cholangitis (1) · Connective Tissue Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Digestive System Diseases (1) · Disease Attributes (1)
BID protein, human (1) · Cyclophosphamide (1) · Levetiracetam (1) · simtuzumab (1) · tabalumab (1)
Duke University (1) · Eli Lilly and Company (1) · Gilead Sciences (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (4) · Canada (2) · Germany (2) · Belgium (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · France (1) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Romania (1) · Russia (1)
Daniel E. Furst, MD (1) · Keith M. Sullivan, MD (1) · Leslie J. Crofford, MD (1) · Maureen D. Mayes, MD, MPH (1) · Peter A. McSweeney, MD (1) · Richard A. Nash, MD (1) · Richard S Bedlack, MD, PhD (1)
PMID 20708086, PMID 20800376, PMID 23418384, PMID 28602891, PMID 29298160, PMID 30153359, PMID 33131208, PMID 34533286, PMID 35108379, PMID 35904231, PMID 38967589, PMID 39996122